PRTAPROTHENA CORP PUBLIC LTD CO

Nasdaq prothena.com


$ 23.03 $ 0.00 (0 %)    

Wednesday, 08-May-2024 12:38:47 EDT
QQQ $ 439.77 $ 1.54 (0.35 %)
DIA $ 389.26 $ 1.03 (0.27 %)
SPY $ 516.50 $ 1.24 (0.24 %)
TLT $ 90.33 $ 0.02 (0.02 %)
GLD $ 214.49 $ 0.87 (0.41 %)
$ 23.54
$ 23.03
$ 23.02 x 100
$ 23.08 x 100
$ 22.73 - $ 23.28
$ 19.65 - $ 79.38
559,154
na
1.25B
$ 1.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-22-2024 12-31-2023 10-K
2 11-02-2023 09-30-2023 10-Q
3 08-03-2023 06-30-2023 10-Q
4 05-04-2023 03-31-2023 10-Q
5 02-28-2023 12-31-2022 10-K
6 11-03-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-25-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-05-2021 06-30-2021 10-Q
12 05-11-2021 03-31-2021 10-Q
13 02-26-2021 12-31-2020 10-K
14 11-04-2020 09-30-2020 10-Q
15 08-06-2020 06-30-2020 10-Q
16 05-06-2020 03-31-2020 10-Q
17 03-03-2020 12-31-2019 10-K
18 11-05-2019 09-30-2019 10-Q
19 08-06-2019 06-30-2019 10-Q
20 05-07-2019 03-31-2019 10-Q
21 03-15-2019 12-31-2018 10-K
22 11-06-2018 09-30-2018 10-Q
23 08-07-2018 06-30-2018 10-Q
24 05-09-2018 03-31-2018 10-Q
25 02-26-2018 12-31-2017 10-K
26 11-07-2017 09-30-2017 10-Q
27 08-09-2017 06-30-2017 10-Q
28 05-09-2017 03-31-2017 10-Q
29 02-27-2017 12-31-2016 10-K
30 11-02-2016 09-30-2016 10-Q
31 08-02-2016 06-30-2016 10-Q
32 05-04-2016 03-31-2016 10-Q
33 02-25-2016 12-31-2015 10-K
34 11-02-2015 09-30-2015 10-Q
35 08-05-2015 06-30-2015 10-Q
36 05-06-2015 03-31-2015 10-Q
37 03-13-2015 12-31-2014 10-K
38 11-04-2014 09-30-2014 10-Q
39 08-05-2014 06-30-2014 10-Q
40 05-05-2014 03-31-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 prothena-announces-review-on-birtamimab-mechanism-of-action-and-pharmacological-characteristics-published-in-leukemia--lymphoma

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational t...

 cantor-fitzgerald-reiterates-overweight-on-prothena-corp

Cantor Fitzgerald analyst Charles Duncan reiterates Prothena Corp (NASDAQ:PRTA) with a Overweight.

 hc-wainwright--co-maintains-buy-on-prothena-corp-maintains-90-price-target

HC Wainwright & Co. analyst Andrew Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $90 price target.

 jmp-securities-maintains-market-outperform-on-prothena-corp-raises-price-target-to-85

JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price targ...

 rbc-capital-maintains-sector-perform-on-prothena-corp-lowers-price-target-to-35

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and lowers the price target f...

 prothena-corp-q4-2023-gaap-eps-126-misses-122-estimate-sales-31600k-miss-215m-estimate

Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(1.2...

 earnings-scheduled-for-february-15-2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on rev...

 why-ups-shares-are-trading-lower-by-8-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of United Parcel Service, Inc. (NYSE: UPS) fell sharply during Tuesday’s session after the company reported worse-than-e...

 b-of-a-securities-downgrades-prothena-corp-to-neutral-lowers-price-target-to-38

B of A Securities analyst Tazeen Ahmad downgrades Prothena Corp (NASDAQ:PRTA) from Buy to Neutral and lowers the price targe...

 rbc-capital-maintains-sector-perform-on-prothena-corp-lowers-price-target-to-36

RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and lowers the price target f...

 cantor-fitzgerald-maintains-overweight-on-prothena-corp-lowers-price-target-to-87

Cantor Fitzgerald analyst Charles Duncan maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and lowers the price target...

 hewlett-packard-enterprise-hologic-and-other-big-stocks-moving-lower-in-tuesdays-pre-market-session

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 100 points on Tuesday. Shares of Hewlet...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION